Analysts project STAAR Surgical to report Q2 2026 revenue of $106.5 million and earnings per share of $0.05, while the stock trades at $42.50, notably below the $52.00 average price target. The primary focus for investors this quarter is the volume growth of EVO ICL lens sales, particularly within the critical China and U.S. markets.
Markets are looking for evidence that the company's aggressive direct-to-consumer marketing in the United States is successfully yielding higher adoption rates among refractive surgery patients. Additionally, signs of stabilizing consumer demand in China will be critical after recent periods of macroeconomic volatility impacted elective medical procedure volumes.